Thiogenesis Therapeutics, Corp. (TSXV:TTI)
Canada · Delayed Price · Currency is CAD 0.6000
+0.0200 (3.45%)
At close: Jun 9, 2026
Thiogenesis Therapeutics Market Cap
Thiogenesis Therapeutics has a market cap or net worth of CAD 31.1 million as of June 10, 2026. Its market cap has increased by 2.40% in one year.
Market Cap
31.10M
Enterprise Value
30.20M
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
0.60
Market Cap Chart
Since April 13, 2022, Thiogenesis Therapeutics's market cap has increased from 13.96M to 31.10M, an increase of 122.87%. That is a compound annual growth rate of 21.25%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 9, 2026 | 31.10M | -7.69% |
| Dec 31, 2025 | 33.69M | 22.03% |
| Dec 31, 2024 | 27.61M | -17.40% |
| Dec 29, 2023 | 33.43M | 48.30% |
| Dec 30, 2022 | 22.54M | 61.52% |
| Apr 13, 2022 | 13.96M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| NurExone Biologic | 54.31M |
| MedMira | 42.10M |
| Medicenna Therapeutics | 38.77M |
| Microbix Biosystems | 38.57M |
| Defence Therapeutics | 37.89M |
| BriaCell Therapeutics | 36.80M |
| Resverlogix | 34.38M |
| Quantum BioPharma | 34.23M |